Document is current

Article History

Received: 16 June 2016

Revised: 17 July 2016

Accepted: 5 August 2016

First Online: 18 August 2016

Compliance with ethical standards

:

: This work was partially supported by Grants-in-Aid for Scientific Research B (H.T.; 15H04994), Grant-in-Aid for Scientific Research C (S.U.; 16 K11320), Grant-in-Aid for Young Scientists B (K.K.; 16 K20313), Chukyo Longevity Medical and Promotion Foundation (H.K.), Takeda Medical Research Foundation (H.K.). These sponsors had no role in the design or conduct of this research.

: H. Terasaki received personal fees from Bayer HealthCare, Novartis, Santen, Wakamoto, and Pfizer. H. Terasaki received research funding from Novartis, Santen, Wakamoto, and Pfizer.

: H. Terasaki had Grants-in-Aid for Scientific Research B (15H04994) and received personal fees from Bayer HealthCare, Novartis, Santen, Wakamoto, and Pfizer. H. Terasaki received research funding from Novartis, Santen, Wakamoto, and Pfizer.S. Ueno had Grant-in-Aid for Scientific Research C (16 K11320). K, Kataoka had Grant-in-Aid for Young Scientists B (16 K20313). H. Kaneko had financial support from Chukyo longevity medical and promotion foundation, and Takeda Medical Research Foundation.

: The procedures performed in the study were in accordance with the ethical standards of the Nagoya University Hospital Ethics Review Board and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The Nagoya University Hospital Ethics Review Board approved this retrospective analysis of patient data. For this type of study, formal consent is not required.

: Informed consent was obtained from all individual participants included in the study.